Diabetes Clinical Trials

Showing 5801-5820 of 7,874 trials

Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes

NCT00184613

This trial is conducted in Europe. The objective of the study is to investigate the effect and safety of continously basal delivered insulin aspart given by a pump versus once daily injection of insulin glargine.

DiabetesDiabetes Mellitus, Type 2Delivery Systems

Novo Nordisk A/S22 participantsStarted May 2005

Århus C, Denmark

COMPLETEDPhase 1

Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

NCT00908271

The purpose of this study is to estimate the absolute oral bioavailability of dapagliflozin.

Type 2 Diabetes Mellitus

AstraZeneca7 participantsStarted Jul 2009

Madison, Wisconsin, United States

COMPLETEDPhase 1

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects

NCT00839683

Phase A - To assess the effect of simvastatin on the pharmacokinetics (PK) of dapagliflozin and to determine the effect of dapagliflozin on the PK of simvastatin, when simvastatin and dapagliflozin are coadministered in healthy subjects. Phase B - To assess the effect of valsartan on the PK of dapagliflozin and to determine the effect of dapagliflozin on the PK of valsartan, when valsartan and dapagliflozin are coadministered in healthy subjects

Type 2 Diabetes Mellitus

AstraZeneca24 participantsStarted Feb 2009

Neptune City, New Jersey, United States

COMPLETEDPhase 1

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

NCT00930865

To assess the potential pharmacokinetic (PK) interactions of bumetanide and dapagliflozin following multiple doses of 1 mg bumetanide and 10 mg dapagliflozin in healthy subjects

Type 2 Diabetes Mellitus

AstraZeneca42 participantsStarted Jul 2009

Austin, Texas, United States

Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes

Study of the Absolute Oral Bioavailability of Dapagliflozin in Healthy Subjects

Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Related Searches

Study of the Effect of Dapagliflozin on the Pharmacokinetics of Warfarin or Digoxin in Healthy Subjects

A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Bangladesh

Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

The Public Private Partnership Addressing Literacy-Numeracy to Improve Diabetes Care

Observational Study of Type 1 Diabetics Switching From Human Insulins to Modern Insulin Analogues

NovoLet® Acceptance Study Within the Hospital Practise in Indonesia

Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin

Fear of Hypoglycemia and Glycemic Variability

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

Incretin Effect on the Immunological Phenotype

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)

Glycemic Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus

Role of Carnosine as an Adjuvant Therapy for Diabetic Nephropathy in Pediatrics With Type 1 Diabetes

Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI

Diabetes Prevention and Control in the Workplace: A Pilot Study

Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine